يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"Rhiannon, Maudsley"', وقت الاستعلام: 1.12s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    المؤلفون: Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty

    المصدر: npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)

    مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/2374-4677

    URL الوصول: https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f3ddb7682626f66115790cb0108aba
    https://doi.org/10.1158/1078-0432.22476300.v1

    أضف إلى المفضلة
  3. 3
    Data from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c1b1cc28095071714876d36a725e47
    https://doi.org/10.1158/1078-0432.c.6529365.v1

    أضف إلى المفضلة
  4. 4
    Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc68c5e9ff3cae038afb89d5bd3f604
    https://doi.org/10.1158/1078-0432.22476294

    أضف إلى المفضلة
  5. 5
    Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a0265a5795450271c65b9e3919ea10
    https://doi.org/10.1158/1078-0432.22476291.v1

    أضف إلى المفضلة
  6. 6
    Supplementary material from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

    المؤلفون: Jan H.M. Schellens, James Yates, Gaia Schiavon, Paul Rugman, Vicky Rowlands, Martin Pass, Rhiannon Maudsley, Justin P.O. Lindemann, Peter Lawrence, Andrew Foxley, Paul Elvin, Elza C. de Bruin, Barry R. Davies, Marie Cullberg, Claire Corcoran, S.Y. Amy Cheung, T. Hedley Carr, J. Carl Barrett, Helen Ambrose, Mathew Tall, Michelle D. Garrett, Peter Kabos, Shannon N. Westin, Benoit You, Philippe L. Bedard, Gerald Batist, J. Alejandro Pérez-Fidalgo, Emma J. Dean, Udai Banerji

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3d8d839a51fc0d03f0146dcc4e0fb1
    https://doi.org/10.1158/1078-0432.22464402

    أضف إلى المفضلة
  7. 7
    Data from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

    المؤلفون: Jan H.M. Schellens, James Yates, Gaia Schiavon, Paul Rugman, Vicky Rowlands, Martin Pass, Rhiannon Maudsley, Justin P.O. Lindemann, Peter Lawrence, Andrew Foxley, Paul Elvin, Elza C. de Bruin, Barry R. Davies, Marie Cullberg, Claire Corcoran, S.Y. Amy Cheung, T. Hedley Carr, J. Carl Barrett, Helen Ambrose, Mathew Tall, Michelle D. Garrett, Peter Kabos, Shannon N. Westin, Benoit You, Philippe L. Bedard, Gerald Batist, J. Alejandro Pérez-Fidalgo, Emma J. Dean, Udai Banerji

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23540265cf512e0b58e65211bace9f79
    https://doi.org/10.1158/1078-0432.c.6525705.v1

    أضف إلى المفضلة
  8. 8
    Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer

    المؤلفون: Nicholas Turner, Christos Vaklavas, Emiliano Calvo, Javier Garcia-Corbacho, Jason Incorvati, Manuel Ruiz Borrego, Chris Twelves, Anne Armstrong, Begoña Bermejo, Erika Hamilton, Mafalda Oliveira, Eva Ciruelos, Peter Kabos, Manish R Patel, Maria Borrell, Howard Burris, Bruno de Paula, Alejandro Falcon, Cristina Hernando, Irene Moreno, Ciara S. O’Brien, Elena Shagisultanova, Ivan Victoria Ruiz, Judy S. Wang, Mei Wei, Tim Brier, Danielle Carroll, Carmela Ciardullo, Lisa Gibbons, itziar irurzun-Arana, Tony Jack, bistra kirova, Teresa Klinowska, Justin Lindemann, Julie Maidment, Alastair Mathewson, Rhiannon Maudsley, Robert McEwen, Christopher Morrow, Andy Sykes, Richard D. Baird

    المساهمون: Baird, Richard [0000-0001-7071-6483], Apollo - University of Cambridge Repository

    مصطلحات موضوعية: Cancer Research, Oncology, Clinical Research, 6.1 Pharmaceuticals, Breast Cancer, Clinical Trials and Supportive Activities, 32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Estrogen, 6 Evaluation of treatments and therapeutic interventions, Cancer

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b0f1e0fcbdd82a029a528d47540d2
    https://www.repository.cam.ac.uk/handle/1810/350214

    أضف إلى المفضلة
  9. 9
    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    المؤلفون: Michele Moschetta, T. Hedley Carr, Robert McEwen, Alison M. Schram, Myria Nikolaou, Sarat Chandarlapaty, José Baselga, Gaia Schiavon, Funda Meric-Bernstam, Lillian M. Smyth, David M. Hyman, Andrea Li Ann Wong, Joana Hauser, Rhiannon Maudsley, Justin P.O. Lindemann, Iben Spanggaard, Andrew Foxley, Helen Ambrose, Pedram Razavi, Udai Banerji, Elza C. de Bruin, Carolina Salinas-Souza, Komal Jhaveri, Peter Kabos, Gerald Batist, Ana Lluch, Andrea Varga

    المصدر: npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
    NPJ Breast Cancer

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Article, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Maculopapular rash, medicine, PTEN, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Adverse effect, RC254-282, biology, Fulvestrant, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Metastatic breast cancer, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, medicine.symptom, business, Estrogen receptor alpha, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee9a19dea3a5088d0f7e429bfc57f85
    https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b

    Find this article in full text from ProQuest
    أضف إلى المفضلة
  10. 10
    Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

    المؤلفون: Andy Sykes, Christopher J. Morrow, Richard D. Baird, Teresa Klinowska, Rhiannon Maudsley, Marta Capelán Rodríguez, Manuel Ruiz-Borrego, Tim Brier, Bistra Kirova, Justin P.O. Lindemann, Nitharsan Sathiyayogan, Christina Hernando, Julia Lai-Kwon, Javier Garcia-Corbacho, Judy S. Wang, Begoña Bermejo de las Heras, Steven Fox, Mafalda Oliveira, Chris Leach, Eva Maria Ciruelos Gil, Anne C Armstrong, Richard Mather, Erika Hamilton, Manish R. Patel, Jason Incorvati, Udai Banerji, Valentina Boni, Chris Twelves, Ivan Victoria Ruiz, Bruno de Paula, Alejandro González, Li Zhang, Anosheh Afghani, Peter Kabos, Christos Vaklavas, Adam L. Cohen

    المصدر: Cancer Research. 81:PS11-05

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, Fulvestrant, Combination therapy, business.industry, Population, Phases of clinical research, Palbociclib, medicine.disease, Discontinuation, Breast cancer, Tolerability, Internal medicine, medicine, business, education, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a72b8540deb1a95e3a1f45931a47ee6e
    https://doi.org/10.1158/1538-7445.sabcs20-ps11-05

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء